Fortress Biotech Net Income
| FBIO Stock | USD 3.61 0.12 3.44% |
As of the 16th of February 2026, Fortress Biotech shows the Downside Deviation of 4.59, coefficient of variation of 782.51, and Mean Deviation of 3.63. Fortress Biotech technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
Fortress Biotech Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 1.5083 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -108.8 M | -114.2 M | |
| Net Loss | -108.8 M | -114.2 M | |
| Net Loss | -58.2 M | -61.1 M | |
| Net Loss | (1.99) | (2.09) | |
| Net Income Per E B T | 0.44 | 0.59 |
Fortress | Net Income | Build AI portfolio with Fortress Stock |
Evaluating Fortress Biotech's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Fortress Biotech's fundamental strength.
Latest Fortress Biotech's Net Income Growth Pattern
Below is the plot of the Net Income of Fortress Biotech over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Fortress Biotech financial statement analysis. It represents the amount of money remaining after all of Fortress Biotech operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Fortress Biotech's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Fortress Biotech's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (120.86 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Fortress Net Income Regression Statistics
| Arithmetic Mean | (47,595,321) | |
| Coefficient Of Variation | (44.44) | |
| Mean Deviation | 15,681,618 | |
| Median | (45,997,000) | |
| Standard Deviation | 21,150,459 | |
| Sample Variance | 447.3T | |
| Range | 82.8M | |
| R-Value | (0.50) | |
| Mean Square Error | 359.1T | |
| R-Squared | 0.25 | |
| Significance | 0.04 | |
| Slope | (2,082,986) | |
| Total Sum of Squares | 7157.5T |
Fortress Net Income History
Other Fundumenentals of Fortress Biotech
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Fortress Biotech Net Income component correlations
Fortress Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Fortress Biotech is extremely important. It helps to project a fair market value of Fortress Stock properly, considering its historical fundamentals such as Net Income. Since Fortress Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Fortress Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Fortress Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Fortress diversify its offerings? Factors like these will boost the valuation of Fortress Biotech. Market participants price Fortress higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Fortress Biotech data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.12) | Revenue Per Share | Quarterly Revenue Growth 0.205 | Return On Assets | Return On Equity |
Fortress Biotech's market price often diverges from its book value, the accounting figure shown on Fortress's balance sheet. Smart investors calculate Fortress Biotech's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Fortress Biotech's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Fortress Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fortress Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fortress Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Fortress Biotech 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Fortress Biotech's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Fortress Biotech.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in Fortress Biotech on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding Fortress Biotech or generate 0.0% return on investment in Fortress Biotech over 90 days. Fortress Biotech is related to or competes with XBiotech, Nutriband, Vaxart, CervoMed, Adagene, Relmada Therapeutics, and Gain Therapeutics. Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology produc... More
Fortress Biotech Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Fortress Biotech's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Fortress Biotech upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.59 | |||
| Information Ratio | 0.1134 | |||
| Maximum Drawdown | 29.21 | |||
| Value At Risk | (6.45) | |||
| Potential Upside | 10.11 |
Fortress Biotech Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Fortress Biotech's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Fortress Biotech's standard deviation. In reality, there are many statistical measures that can use Fortress Biotech historical prices to predict the future Fortress Biotech's volatility.| Risk Adjusted Performance | 0.1115 | |||
| Jensen Alpha | 0.4591 | |||
| Total Risk Alpha | 0.2498 | |||
| Sortino Ratio | 0.12 | |||
| Treynor Ratio | 0.2418 |
Fortress Biotech February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1115 | |||
| Market Risk Adjusted Performance | 0.2518 | |||
| Mean Deviation | 3.63 | |||
| Semi Deviation | 4.16 | |||
| Downside Deviation | 4.59 | |||
| Coefficient Of Variation | 782.51 | |||
| Standard Deviation | 4.85 | |||
| Variance | 23.56 | |||
| Information Ratio | 0.1134 | |||
| Jensen Alpha | 0.4591 | |||
| Total Risk Alpha | 0.2498 | |||
| Sortino Ratio | 0.12 | |||
| Treynor Ratio | 0.2418 | |||
| Maximum Drawdown | 29.21 | |||
| Value At Risk | (6.45) | |||
| Potential Upside | 10.11 | |||
| Downside Variance | 21.03 | |||
| Semi Variance | 17.31 | |||
| Expected Short fall | (4.36) | |||
| Skewness | (0.03) | |||
| Kurtosis | 1.82 |
Fortress Biotech Backtested Returns
Fortress Biotech appears to be relatively risky, given 3 months investment horizon. Fortress Biotech secures Sharpe Ratio (or Efficiency) of 0.12, which denotes the company had a 0.12 % return per unit of risk over the last 3 months. By reviewing Fortress Biotech's technical indicators, you can evaluate if the expected return of 0.61% is justified by implied risk. Please utilize Fortress Biotech's Coefficient Of Variation of 782.51, mean deviation of 3.63, and Downside Deviation of 4.59 to check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Fortress Biotech holds a performance score of 9. The firm shows a Beta (market volatility) of 2.52, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Fortress Biotech will likely underperform. Please check Fortress Biotech's semi variance, and the relationship between the maximum drawdown and accumulation distribution , to make a quick decision on whether Fortress Biotech's price patterns will revert.
Auto-correlation | -0.54 |
Good reverse predictability
Fortress Biotech has good reverse predictability. Overlapping area represents the amount of predictability between Fortress Biotech time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Fortress Biotech price movement. The serial correlation of -0.54 indicates that about 54.0% of current Fortress Biotech price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.54 | |
| Spearman Rank Test | -0.49 | |
| Residual Average | 0.0 | |
| Price Variance | 0.16 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Fortress Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Fortress Biotech reported net income of (120.86 Million). This is 135.41% lower than that of the Biotechnology sector and 272.54% lower than that of the Health Care industry. The net income for all United States stocks is 121.17% higher than that of the company.
Fortress Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Fortress Biotech's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Fortress Biotech could also be used in its relative valuation, which is a method of valuing Fortress Biotech by comparing valuation metrics of similar companies.Fortress Biotech is currently under evaluation in net income category among its peers.
Fortress Biotech ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Fortress Biotech's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Fortress Biotech's managers, analysts, and investors.Environmental | Governance | Social |
Fortress Biotech Institutional Holders
Institutional Holdings refers to the ownership stake in Fortress Biotech that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Fortress Biotech's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Fortress Biotech's value.| Shares | 180 Wealth Advisors, Llc | 2025-06-30 | 93 K | Atria Investments Llc | 2025-06-30 | 88.8 K | Integrated Wealth Concepts Llc | 2025-06-30 | 68 K | Commonwealth Equity Services Inc | 2025-06-30 | 61.5 K | Pfg Investments, Llc | 2025-06-30 | 55.4 K | Panagora Asset Management Inc | 2025-06-30 | 50.1 K | Two Sigma Investments Llc | 2025-06-30 | 45.8 K | Susquehanna International Group, Llp | 2025-06-30 | 45.6 K | Weaver Consulting Group | 2025-06-30 | 44.9 K | Summit Financial, Llc | 2025-06-30 | 1 M | Vanguard Group Inc | 2025-06-30 | 852.9 K |
Fortress Fundamentals
| Return On Equity | -2.05 | ||||
| Return On Asset | -0.34 | ||||
| Profit Margin | 0.06 % | ||||
| Operating Margin | (0.39) % | ||||
| Current Valuation | 93.97 M | ||||
| Shares Outstanding | 31.04 M | ||||
| Shares Owned By Insiders | 20.46 % | ||||
| Shares Owned By Institutions | 14.80 % | ||||
| Number Of Shares Shorted | 4.58 M | ||||
| Price To Earning | (2.92) X | ||||
| Price To Book | 2.00 X | ||||
| Price To Sales | 1.80 X | ||||
| Revenue | 57.67 M | ||||
| Gross Profit | 19.93 M | ||||
| EBITDA | (104.49 M) | ||||
| Net Income | (120.86 M) | ||||
| Cash And Equivalents | 208.35 M | ||||
| Cash Per Share | 1.92 X | ||||
| Total Debt | 75.96 M | ||||
| Debt To Equity | 1.24 % | ||||
| Current Ratio | 2.43 X | ||||
| Book Value Per Share | 1.80 X | ||||
| Cash Flow From Operations | (80.19 M) | ||||
| Short Ratio | 3.91 X | ||||
| Earnings Per Share | (0.12) X | ||||
| Price To Earnings To Growth | (0.10) X | ||||
| Target Price | 10.75 | ||||
| Number Of Employees | 101 | ||||
| Beta | 1.42 | ||||
| Market Capitalization | 112.05 M | ||||
| Total Asset | 144.22 M | ||||
| Retained Earnings | (740.87 M) | ||||
| Working Capital | 18.97 M | ||||
| Current Asset | 99.94 M | ||||
| Current Liabilities | 10.58 M | ||||
| Net Asset | 144.22 M |
About Fortress Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Fortress Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fortress Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fortress Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Fortress Biotech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Fortress Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Fortress Biotech will appreciate offsetting losses from the drop in the long position's value.Moving against Fortress Stock
| 0.65 | DRMA | Dermata Therapeutics | PairCorr |
| 0.64 | OB3 | OPTIBIOTIX HLTH PLC | PairCorr |
| 0.62 | ABNX | Abionyx Pharma SA | PairCorr |
| 0.48 | OSE | OSE Pharma SA | PairCorr |
| 0.45 | VANI | Vivani Medical | PairCorr |
The ability to find closely correlated positions to Fortress Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Fortress Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Fortress Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Fortress Biotech to buy it.
The correlation of Fortress Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Fortress Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Fortress Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Fortress Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out To learn how to invest in Fortress Stock, please use our How to Invest in Fortress Biotech guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Will Biotechnology sector continue expanding? Could Fortress diversify its offerings? Factors like these will boost the valuation of Fortress Biotech. Market participants price Fortress higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Fortress Biotech data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.12) | Revenue Per Share | Quarterly Revenue Growth 0.205 | Return On Assets | Return On Equity |
Fortress Biotech's market price often diverges from its book value, the accounting figure shown on Fortress's balance sheet. Smart investors calculate Fortress Biotech's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Fortress Biotech's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Fortress Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fortress Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fortress Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.